^(125)I粒子组织间植入治疗头颈部复发和转移恶性肿瘤

Interstitial Implantation of ^(125)I seeds for Recurrent or Metastatic Malignant Tumor at the Head and Neck

目的探讨125I植入治疗复发和转移头颈部恶性肿瘤的可行性。方法2003年1月~2007年7月,对29例头颈部癌术后或放化疗后复发或转移,在局部浸润麻醉下,CT、B超或腔内镜引导125I粒子植入术,粒子间距0.5~1.0cm。肿瘤周边匹配剂量(matched peripheral dose,MPD)90~160Gy,粒子活度29.6MBq。结果29例均顺利完成手术,每例植入粒子12~67颗,中位数23颗。术后未发生出血、感染、粒子移位等严重并发症。29例随访3~24个月,平均16个月,局部控制率术后3个月为55%(16/29),6个月71%(20/28),12个月45%(10/22),2年36%(5/14)。结论放射性125I粒子植入治疗复发和转移头颈部肿瘤可行,近期疗效可靠。

Objective To evaluate the feasibility of interstitial implantation of ^(125)I seeds for recurrent or metastatic malignant tumor at the Head and Neck.Methods From January 2003 to July 2007,29 patients received interstitial implantation of ^(125)I seeds in our hospital because of recurrent or metastatic malignant tumors at the head or neck after surgery or chemotherapy.Under local anesthesia and guidance of CT,B-ultrasonography,or endoscopy,^(125)I seeds were implanted into the tumor tissues with intervals of...